公开(公告)号：US20150175710A1

公开(公告)日：2015-06-25

申请号：US14580127

申请日：2014-12-22

Applicant: DEVELOPMENT CENTER FOR BIOTECHNOLOGY

Inventor： Shih-Chong Tsai ,  Mingl Chang ,  Ta-Tung Yuan ,  Shih-Chi Tseng ,  Shyi-Jou Chen ,  Wei-Tso Chia ,  Hsin-Yun Wang

IPC: C07K16/40 ,  A61K39/39 ,  A61K39/395

CPC classification number: A61K39/39 ,  A61K39/3955 ,  A61K2039/505 ,  B63B1/121 ,  B63B15/02 ,  B63B2001/123 ,  B63B2015/005 ,  B63H9/08 ,  C07K16/40 ,  C07K2317/34 ,  C07K2317/76 ,  C07K2317/92

Abstract: A method for treating an inflammatory disease or an immune disorder includes administering to a subject in need of such treatment an antagonist against ENO1. The antagonist binds ENO1 and inhibits ENO1 plasminogen receptor activity. The antagonist may be an anti-human ENO1 antibody, or an scFv, Fab, or F(ab)2 fragment thereof, that specifically binds to human ENO1 (GenBank: AAH50642.1) for the treatment of an inflammatory disease or an immune disorder, which may be multiple sclerosis, rheumatoid arthritis, Crohn's disease, ulcerative colitis, systemic Lupus erythematosus, chronic obstructive pulmonary disease (COPD), asthma, allergy, psoriasis, type 1 diabetes mellitus, artherosclerosis or osteoporosis.

Abstract translation: 用于治疗炎性疾病或免疫疾病的方法包括向需要这种治疗的受试者施用针对ENO1的拮抗剂。 拮抗剂结合ENO1并抑制ENO1纤溶酶原受体活性。 拮抗剂可以是特异性结合人ENO1（GenBank：AAH50642.1）用于治疗炎性疾病或免疫疾病的抗人ENO1抗体或其scFv，Fab或F（ab）2片段） ，可能是多发性硬化症，类风湿性关节炎，克罗恩病，溃疡性结肠炎，系统性红斑狼疮，慢性阻塞性肺病（COPD），哮喘，过敏，牛皮癣，1型糖尿病，动脉粥样硬化或骨质疏松症。

公开(公告)号：US09750804B2

公开(公告)日：2017-09-05

申请号：US14580127

申请日：2014-12-22

Applicant: Development Center for Biotechnology ,  National Health Research Institutes

Inventor： Shih-Chong Tsai ,  Mingl Chang ,  Ta-Tung Yuan ,  Shih-Chi Tseng ,  Shyi-Jou Chen ,  Wei-Tso Chia ,  Hsin-Yun Wang ,  Neng-Yao Shih ,  Ko-Jiunn Liu ,  Li-Tzong Chen

IPC: C07K16/28 ,  A61K39/39 ,  B63B15/02 ,  A61K39/395 ,  C07K16/40 ,  B63B1/12 ,  B63H9/08 ,  B63B15/00 ,  A61K39/00

CPC classification number: A61K39/39 ,  A61K39/3955 ,  A61K2039/505 ,  B63B1/121 ,  B63B15/02 ,  B63B2001/123 ,  B63B2015/005 ,  B63H9/08 ,  C07K16/40 ,  C07K2317/34 ,  C07K2317/76 ,  C07K2317/92

Abstract: A method for treating an inflammatory disease or an immune disorder includes administering to a subject in need of such treatment an antagonist against ENO1. The antagonist binds ENO1 and inhibits ENO1 plasminogen receptor activity. The antagonist may be an anti-human ENO1 antibody, or an scFv, Fab, or F(ab)2 fragment thereof, that specifically binds to human ENO1 (GenBank: AAH50642.1) for the treatment of an inflammatory disease or an immune disorder, which may be multiple sclerosis, rheumatoid arthritis, Crohn's disease, ulcerative colitis, systemic Lupus erythematosus, chronic obstructive pulmonary disease (COPD), asthma, allergy, psoriasis, type 1 diabetes mellitus, artherosclerosis or osteoporosis.